Business
Ocular Therapeutix™ to Announce Topline Data for SOL-1 Phase 3 Superiority Trial in Wet AMD on Tuesday, February 17, 2026
Ocular to host webcast scheduled for Tuesday, February 17, 2026, at 8:00 AM ET Detailed SOL-1 data to be presented at the 49th Macula Society Annual Meeting BEDFORD, Mass., Feb. 13, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that the Company will host a webcast to review the topline results of the SOL-1 Phase 3 superiority clinical trial of AXPAXLI™ (also known
About this update from Ocular Therapeutix, Inc.
[{"type":"image","alt":"Ocular Therapeutix, Inc.","displaySize":"","headline":null,"caption":"Ocular Therapeutix, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":101,"url":"https://media.zenfs.com/en/globenewswire.com/67aba0a08455988daf68787482afba8f"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/jQkRmXXuVY17YPwf6FJ8wQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE0MTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/67aba0a08455988daf68787482afba8f","width":300,"height":101}},"lazy":false},{"type":"text","content":"Ocular to host webcast scheduled for Tuesday, February 17, 2026, at 8:00 AM ET","length":78,"tagName":"p"},{"type":"text","content":"Detailed SOL-1 data to be presented at the 49th Macula Society Annual Meeting ","length":77,"tagName":"p"},{"type":"text","content":"BEDFORD, Mass., Feb. 13, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that the Company will host a webcast to review the topline results of the SOL-1 Phase 3 superiority clinical trial of AXPAXLI™ (also known as OTX-TKI), for the treatment of wet age-related macular degeneration (wet AMD), on Tuesday, February 17, 2026. Detailed data will be presented at the 49th Macula Society Annual Meeting between February 25 – 28, 2026.","length":561,"tagName":"p"},{"type":"text","content":"Click here to register for the virtual webcast, which will begin at 8:00 AM ET.","length":84,"tagName":"p"},{"type":"text","content":"The live and archived webcast can also be accessed by visiting the Ocular Therapeutix website on the Events and Presentations section of the Investor Relations page. A replay of the webcast will be archived for at least 30 days.","length":228,"tagName":"p"},{"type":"text","content":"About Ocular Therapeutix, Inc.Ocular Therapeutix, Inc. is an integrated biopharmaceutical company committed to redefining the retina experience. AXPAXLI™ (also known as OTX-TKI), Ocular’s investigational product candidate for retinal disease, is an axitinib intravitreal hydrogel based on its ELUTYX™ proprietary bioresorbable hydrogel-based formulation technology. AXPAXLI is currently in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD) and diabetic retinal disease, including non-proliferative d...